Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2025-09-25

FDA Approved: ALYFTREK — Supplemental Application (Vertex Pharmaceuticals Incorporated)

View source ↗

Summary

FDA approved a supplemental application for Alyftrek (vanzacaftor, tezacaftor, and deutivacaftor) from Vertex Pharmaceuticals Incorporated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • ALYFTREK (VANZACAFTOR, TEZACAFTOR, AND DEUTIVACAFTOR)

Snippet

SUPPL AP for ALYFTREK (VANZACAFTOR, TEZACAFTOR, AND DEUTIVACAFTOR)